Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Carbon ion radiotherapy: Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
Study summary
The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.
Eligibility
Primary outcome measure(s)
- 2-year cumulative local regional progression rate (LRP) — From the date of the initiation of radiotherapy until the date of first documented occurrence of local regional progression, assessed up to 24 months.
LRP was defined as the percentage of patients with local disease progression (within irradiated area) in the intentional population.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shanghai Proton and Heavy Ion Center | Shanghai | China | Recruiting |
More Shanghai Proton and Heavy Ion Center trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05424159 on ClinicalTrials.gov ↗ ← All trials in China